0
selected
-
1.
Circulating Selenium and Cardiovascular or All-Cause Mortality in the General Population: a Meta-Analysis.
Xiang, S, Dai, Z, Man, C, Fan, Y
Biological trace element research. 2020;(1):55-62
Abstract
The association of circulating selenium level with mortality remains controversial. This meta-analysis investigated the association between elevated circulating selenium level and cardiovascular or all-cause mortality in the general population. PubMed and Embase databases (up to January 20, 2019) were searched for observational studies or post hoc analyses of randomized controlled trials that evaluated the association between elevated circulating selenium level and cardiovascular or all-cause mortality in the general population. Twelve observational studies (ten cohort and two case-control studies) with a total of 25,667 individuals were included. Comparison with the lowest and the highest circulating selenium level showed that the pooled risk ratio (RR) values of all-cause mortality and cardiovascular mortality were 1.36 (95% confidence intervals [CI] 1.18-1.58) and 1.35 (95% CI 1.13-1.62), respectively. When analyzed selenium level as a continuous variable, each standard deviation selenium increase significantly reduced 20% all-cause mortality risk. However, the lowest circulating selenium level was not associated with a high risk of coronary mortality (RR 1.43; 95% CI 0.93-2.19). This meta-analysis indicated that low circulating selenium level was associated with higher risk of cardiovascular or all-cause mortality in the general population. Low circulating selenium level did not confer significant effect on coronary death.
-
2.
Lower circulating zinc and selenium levels are associated with an increased risk of asthma: evidence from a meta-analysis.
Chen, M, Sun, Y, Wu, Y
Public health nutrition. 2020;(9):1555-1562
-
-
Free full text
-
Abstract
OBJECTIVE Previous studies evaluating the associations of circulating Zn and Se levels with asthma have produced inconsistent results. Therefore, we conducted a meta-analysis to summarize and quantitatively synthesize the evidence from observational research. DESIGN Meta-analysis. SETTING We searched PubMed, Web of Science and Scopus databases up to May 2019 for relevant available articles. Random-effects model was adopted to estimate the pooled standardized mean difference (SMD) with 95 % CI. Meta-regression analysis and 'leave-one-out' sensitivity analysis were used to assess heterogeneity. PARTICIPANTS The meta-analysis focused on general populations. RESULTS A total of twenty-six studies for Zn and forty studies for Se were included in the meta-analysis. The overall analyses identified that asthma patients had lower Zn (SMD = -0·40; 95 % CI -0·77, -0·03; I2 = 94·1 %) and Se (SMD = -0·32; 95 % CI -0·48, -0·17; I2 = 90·9 %) levels in serum or plasma compared with healthy controls. After removing the studies that contributed to the heterogeneity, the pooled SMD were -0·26 (95 % CI -0·40, -0·13; I2 = 37·42 %) for Zn and -0·06 (95 % CI -0·13, 0·02; I2 = 43·54 %) for Se. CONCLUSIONS Lower circulating Zn and Se levels might be associated with an increased risk of asthma.
-
3.
A meta-analysis of randomized controlled trials: Efficacy of selenium treatment for sepsis.
Li, S, Tang, T, Guo, P, Zou, Q, Ao, X, Hu, L, Tan, L
Medicine. 2019;(9):e14733
-
-
Free full text
-
Abstract
BACKGROUND To understand the clinical outcomes of selenium therapy in patients with sepsis syndrome, we conducted a meta-analysis of randomized controlled trials (RCT). METHODS A total of 13 RCTs comparing selenium and placebo for patients with sepsis were reviewed systematically. RESULTS However, we could not detect the association of selenium treatment with a decreased mortality at different time course (relative risk [RR] [95% confidence interval, CI]: 0.94 [0.82-1.06] at day 28; 0.73 [0.36-1.47] at day 90; 1.16 [0.78-1.71] at 6 months; respectively). Selenium supplementation did not show favorable efficacy in the incidence of renal failure, secondary infection or duration of mechanical ventilation (RR [95% CI]: 0.65 [0.41-1.03]; 0.96 [0.87-1.06]; standard mean difference [SMD] [95% CI]: 0.17 [-0.30-0.63]; respectively). Interestingly, we found that selenium therapy was benefit for sepsis patients with reduced duration of vasopressor therapy, staying time in intensive care unit and hospital, and incidence of ventilator-associated pneumonia (SMD [95% CI]: -0.75 [-1.37 to -0.13]; -0.15 [CI: -0.25 to -0.04]; -1.22 [-2.44 to -0.01]; RR [95% CI]: 0.61 [0.42-0.89]; respectively). CONCLUSION Based on our findings, intravenous selenium supplementation could not be suggested for routine use.
-
4.
Selenium concentration, dietary intake and risk of hepatocellular carcinoma - A systematic review with meta-analysis.
Gong, Y, Dong, F, Geng, Y, Zhuang, H, Ma, Z, Zhou, Z, Huang, B, Sun, Z, Hou, B
Nutricion hospitalaria. 2019;(6):1430-1437
Abstract
Aim: this study was performed to investigate the association between selenium concentrations, dietary intake, and the risk of hepatocellular carcinoma (HCC). Methods: we identified eligible studies in PubMed and EMBASE databases, in addition to the reference lists of original studies and review articles on this topic, up to 1 Feb 2019. A summary of standardized mean differences (SMD) with 95% confidence intervals (CI) was calculated using a random-effects model. Heterogeneity between studies was assessed using Cochran Q and I2 statistics. Results: finally, a meta-analysis showed that dietary intake of selenium and tissue selenium concentration were not associated with HCC risk (dietary SMD = -0.11, 95% CI: -0.26 to 0.03; tissue SMD = -0.12, 95% CI: -0.56 to 0.33). However, samples from toenail, whole blood, and serum all showed an inverse association with HCC risk (toenail SMD = -0.53, 95% CI: -0.72 to -0.35; whole blood SMD = -2.21, 95% CI: -2.67 to -1.76; tissue SMD = -1.26, 95% CI: -1.71 to -0.81). Dose-response data from few studies showed that an extra increase in serum selenium was dramatically related with a lower risk of HCC (adjusted p-trend < 0.05). This study showed that selenium concentration in toenail, whole blood and serum was inversely associated with HCC risk. Conclusion: increased concentration in serum selenium was related to a lower risk of HCC. However, these results based on dietary intake and tissue samples, which included few studies, did not reach statistical significance.
-
5.
Selenium and Type 2 Diabetes: Systematic Review.
Kohler, LN, Foote, J, Kelley, CP, Florea, A, Shelly, C, Chow, HS, Hsu, P, Batai, K, Ellis, N, Saboda, K, et al
Nutrients. 2018;(12)
Abstract
Several studies have investigated the potential role of selenium (Se) in the development of type 2 diabetes (T2D) with disparate findings. We conducted a systematic review and meta-analysis to synthesize the evidence of any association between Se and T2D. PubMed, Embase, and Scopus were searched following the Preferred Reporting Items for Systematic Reviews and Meta-analysis Approach (PRISMA). Sixteen studies from 15 papers met inclusion criteria defined for this review. Of the 13 observational studies included, 8 demonstrated a statistically significant positive association between concentrations of Se and odds for T2D, with odds ratios (95% confidence intervals) ranging from 1.52 (1.01⁻2.28) to 7.64 (3.34⁻17.46), and a summary odds ratio (OR) (95% confidence interval (CI)) of 2.03 (1.51⁻2.72). In contrast, among randomized clinical trials (RCTs) of Se, a higher risk of T2D was not observed for those who received Se compared to a placebo (OR = 1.18, 95% CI 0.95⁻1.47). Taken together, the results for the relationship between Se and T2D differ between observational studies and randomized clinical trials (RCTs). It remains unclear whether these differences are the result of uncontrolled confounding in the observational studies, or whether there is a modest effect of Se on the risk for T2D that may vary by duration of exposure. Further investigations on the effects of Se on glucose metabolism are needed.
-
6.
Effect of Selenium Supplementation on Lipid Profile: A Systematic Review and Meta-Analysis.
Hasani, M, Djalalinia, S, Sharifi, F, Varmaghani, M, Zarei, M, Abdar, ME, Asayesh, H, Noroozi, M, Kasaeian, A, Gorabi, AM, et al
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2018;(10):715-727
Abstract
Selenium is an essential mineral that plays a key role in plenty of major metabolic processes. A growing body of literature has shown that selenium deficiency leads to an increase in plasma TC and TG levels. This study explores the effect of selenium supplementation on serum level of lipid profile [total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), very low density lipoprotein (VLDL)]. We systematically searched PubMed/MEDLINE, ISI/WOS, and Scopus (from their commencements to Jan 2016) to identify the papers investigating the association between the intake of selenium and lipid profile. Data extracted from the relevant studies were screened. The pooled standardized mean difference was estimated using the random or fixed effects model. Heterogeneity among the studies was assessed using Q-test. Of the potentially relevant articles screened, 11 articles including 1221 participants were included in this meta-analysis. Results of meta-analysis showed that intake of selenium resulted in a statistically significant improvement in TC, [(SMD): -0.13, 95% CI: (-0.24, -0.02)], TG [(SMD): -0.19, 95% CI: (-0.38, -0.01)] and VLDL [(SMD): -0.34, 95% CI: (-0.63, -0.05)]. The selenium supplementation did not significantly improve lipid profile such as LDL [(SMD): -0.08, 95% CI: (-0.036, 0.19)], HDL [(SMD): 0.01, 95% CI: (-0.164, 0.18)], HDL/TC ratio [(SMD): 0.025, 95% CI: (-0.11, 0.16)], non-HDL-C [(SMD): 0.018, 95% CI: (-0.13, 0.16)]. This meta-analysis suggests that the effect of selenium supplementation on the serum levels of TG and VLDL is marginally significant. However, the supplementation has no effect on other serum lipids. Moreover, the study shows that the effect of selenium supplementation on lipid profile is negative.
-
7.
The association between Selenium and Prostate Cancer: a Systematic Review and Meta-Analysis.
Sayehmiri, K, Azami, M, Mohammadi, Y, Soleymani, A, Tardeh, Z
Asian Pacific journal of cancer prevention : APJCP. 2018;(6):1431-1437
Abstract
Background: Evidence of relationship between selenium and prostate cancer has been inconsistent. The present metaanalysis was conducted to determine relationship between selenium and prostate cancer. Methods: A systematic review and meta-analysis was carried out using preferred reporting items for systematic reviews and meta-analysis (PRISMA). We searched PubMed, Scopus, Web of Science, ScienceDirect, Embase, CINAHL, Cochrane Library, EBSCO and Google scholar search engines and the reference lists of the retrieved papers for relevant data, without any limitation regarding language or time until 2016. Heterogeneity among studies was evaluated using Q test and I2 Index. Finally, a random effects model was used for combining results using STATA software version 11.1. P<0.05 was considered significant. Results: Thirty-eight studies including 36,419 cases and 105,293 controls were included in the final analysis. The pooled relative risk (RR) of relation between selenium and prostate cancer was 0.86 (95% Confidence Interval [CI]:0.78-0.94). Sub-group analyses based on case-control, cohort, and RCT studies gave values of 0.89 (95% CI: 0.80-1.00), 0.77 (95% CI: 0.52-1.14) and 0.90 (95% CI: 0.74-1.09), respectively. RRs based on serum, plasma and nail samples were 0.69 (95% CI: 0.51-0.95), 0.85 (95% CI: 0.61-1.17), 0.66 (95% CI: 0.41-1.05), respectively. According to 10 studies, investigated the relation between advanced prostate cancer and selenium in which the RR was 0.67 (95% CI: 0.52-0.87). Conclusions: This meta-analysis indicated that selenium most probably has a protective role against development of prostate cancer and its progression to advanced stages. Therefore, selenium supplementation can be proposed for prevention of prostate cancer.